Immune cells from a family donor for stubborn virus infections after stem cell transplant
Part of Infections clinical trials.
This trial is testing whether giving special immune cells from a family donor (called CTLs) along with regular antiviral medicine is better than regular medicine alone for people who have a stubborn adenovirus or cytomegalovirus infection after a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 30 years old or younger.
- You had a stem cell transplant.
- You have a viral infection called adenovirus (ADV) or cytomegalovirus (CMV).
- The infection is still present or getting worse after at least 7 days of antiviral medicine, or you can't take antiviral medicine due to side effects, or the virus is resistant to treatment.
- A family member (related donor) is available who matches you well enough and can provide special immune cells.
- You are generally well enough (performance status above 30%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
Hear when a new CMV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.